1-2 of 2
Michael Lyng Wolden
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk

Jan Westerink, Kasper Sommer Matthiessen, Solomon Nuhoho, Udi Fainberg, Michael Lyng Wolden, Helena Bleken Østergaard, Frank Visseren, Naveed Sattar
Journal: Diabetes Care
Diabetes Care 2022;45(5):1211–1218
https://doi.org/10.2337/dc21-1138
Published: 09 March 2022
View article titled, Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk
Open the PDF for Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk in another window
Journal Articles

Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study

Kamlesh Khunti, Melanie Davies, Azeem Majeed, Brian Larsen Thorsted, Michael Lyng Wolden, Sanjoy K. Paul
Journal: Diabetes Care
Diabetes Care 2015;38(2):316–322
https://doi.org/10.2337/dc14-0920
Published: 09 December 2014
View article titled, Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study
Open the PDF for Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study in another window
Includes: Supplementary data